Usana Health Sciences Inc (NYSE: USNA)’s stock price has decreased by -13.76 compared to its previous closing price of 33.21. However, the company has seen a -10.75% decrease in its stock price over the last five trading sessions. seekingalpha.com reported 2025-02-26 that USANA Health Sciences, Inc. (NYSE:USNA ) Q4 2024 Earnings Conference Call February 26, 2025 11:00 AM ET Company Participants Andrew Masuda – IR Jim Brown – President and CEO Brent Neidig – Chief Commercial Officer Doug Hekking – CFO Walter Noot – COO Conference Call Participants Anthony Lebiedzinski – Sidoti Christina Xue – D.A. Davidson Ivan Feinseth – Tigress Financial Partners Doug Lane – Water Tower Research Operator Greetings, and welcome to the USANA Health Sciences’ Fourth Quarter Conference Call.
Is It Worth Investing in Usana Health Sciences Inc (NYSE: USNA) Right Now?
Usana Health Sciences Inc (NYSE: USNA) has a price-to-earnings ratio of 13.08x that is above its average ratio. Additionally, the 36-month beta value for USNA is 0.96. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for USNA is 11.19M and currently, short sellers hold a 6.75% ratio of that float. The average trading volume of USNA on February 28, 2025 was 139.80K shares.
USNA’s Market Performance
USNA’s stock has seen a -10.75% decrease for the week, with a -16.60% drop in the past month and a -28.22% fall in the past quarter. The volatility ratio for the week is 9.97%, and the volatility levels for the past 30 days are at 4.83% for Usana Health Sciences Inc The simple moving average for the last 20 days is -9.46% for USNA stock, with a simple moving average of -27.27% for the last 200 days.
Analysts’ Opinion of USNA
Jefferies, on the other hand, stated in their research note that they expect to see USNA reach a price target of $53, previously predicting the price at $78. The rating they have provided for USNA stocks is “Underperform” according to the report published on July 07th, 2022.
DA Davidson gave a rating of “Neutral” to USNA, setting the target price at $86 in the report published on April 14th of the previous year.
USNA Trading at -14.77% from the 50-Day Moving Average
After a stumble in the market that brought USNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -43.08% of loss for the given period.
Volatility was left at 4.83%, however, over the last 30 days, the volatility rate increased by 9.97%, as shares sank -17.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -23.87% lower at present.
During the last 5 trading sessions, USNA fell by -10.75%, which changed the moving average for the period of 200-days by -38.17% in comparison to the 20-day moving average, which settled at $31.63. In addition, Usana Health Sciences Inc saw -20.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at USNA starting from FULLER GILBERT A, who sale 675 shares at the price of $37.71 back on Nov 04 ’24. After this action, FULLER GILBERT A now owns 0 shares of Usana Health Sciences Inc, valued at $25,457 using the latest closing price.
Jones Paul A., the CHIEF PEOPLE OFFICER of Usana Health Sciences Inc, sale 6,266 shares at $38.38 during a trade that took place back on Aug 13 ’24, which means that Jones Paul A. is holding 0 shares at $240,487 based on the most recent closing price.
Stock Fundamentals for USNA
Current profitability levels for the company are sitting at:
- 0.1 for the present operating margin
- 0.8 for the gross margin
The net margin for Usana Health Sciences Inc stands at 0.06. The total capital return value is set at 0.15. Equity return is now at value 8.17, with 6.09 for asset returns.
Currently, EBITDA for the company is 123.11 million with net debt to EBITDA at -3.27. When we switch over and look at the enterprise to sales, we see a ratio of 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.00.
Conclusion
In conclusion, Usana Health Sciences Inc (USNA) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
